Imaging & Structural Heart · Practice-Changing Data

Rethinking a Sacred Cow: Sublingual Nitroglycerin Before Pre-TAVI CT Angiography

New prospective data presented at SCCT 2026 suggest a long-standing contraindication may be doing more harm than good in appropriately selected patients.

Cardiology & Cardiovascular Investing Digest · Practice Update

Coronary artery disease coexists with severe aortic stenosis in roughly six or seven of every ten patients referred for valve replacement.

Because of that overlap, Society for Cardiovascular Computed Tomography (SCCT) guidance calls for routine coronary assessment as part of pre-procedural planning.

Sublingual nitroglycerin has long been the standard trick for sharpening those images, since it dilates the coronary arteries and reduces motion-related blur.

Yet the same guidance has historically flagged nitroglycerin as relatively contraindicated in severe AS, out of concern that its hypotensive effect could be dangerous in a stenotic, preload-dependent ventricle.

That tension has left many imaging labs either skipping the drug in this population or using it off-protocol without strong evidence either way.

A new prospective study presented at the 2026 SCCT annual scientific meeting directly tests that old assumption.

Mean systolic blood pressure fell after sublingual nitroglycerin and then stabilized through discharge, with no associated symptoms in the majority of patients.

What the Study Found

Investigators enrolled 109 patients with severe AS, mean age 79.4 years, referred for coronary CT angiography ahead of TAVI.

Everyone in the cohort received 0.8 mg of sublingual nitroglycerin, after excluding patients with baseline hypotension, severely reduced ejection fraction, critical AS, or other standard contraindications.

Mean systolic blood pressure dropped from 158 mmHg at baseline to 140 mmHg after the scan and remained stable at 136 mmHg through discharge.

Just over a third of patients, 38.5%, had a drop in systolic pressure greater than 20 mmHg, but none of these drops were tied to symptoms.

The most common side effects were mild and self-limited: headache in 8.2% and dizziness in 7.3%.

Against a propensity-matched control group that did not receive the drug, the nitroglycerin group showed sharply better image quality on nearly every metric the researchers tracked.

Imaging Performance, Head-to-Head

Metric	Nitroglycerin Group	Control Group	P value
Contrast-to-noise ratio	30.4	18.5	<0.001
Signal-to-noise ratio	25.5	15.1	<0.001
Coronary blood volume index	3.1	2.0	<0.001
False-positive scans	8	23	—
Positive predictive value	75.0%	48.9%	0.033
Diagnostic accuracy	84.9%	67.6%	0.036

The nitroglycerin group also had significantly fewer scans classified as the ambiguous CAD-RADS 3 category, meaning fewer equivocal reads that would typically trigger a follow-up invasive study.

Consistent with that, the study group trended toward needing fewer subsequent invasive coronary angiograms, 35.6% versus 49.3% in controls, a 27% relative risk reduction that did not quite reach statistical significance.

Positive predictive value and diagnostic accuracy were both significantly higher in patients who received sublingual nitroglycerin before their scan.

A Practice Change, Not Just a Data Point

The investigators framed their conclusion plainly: sublingual nitroglycerin before CTA in appropriately selected patients with severe AS undergoing TAVI evaluation is safe and well tolerated.

The senior author on the study, who also serves as SCCT's incoming president, told meeting attendees the data have already changed practice at his own center.

The presenting investigator's group now routinely gives sublingual nitroglycerin before pre-TAVR CT in elective, clinically stable patients with severe AS.

Their exclusion criteria mirror the study protocol: baseline systolic blood pressure under 100 mmHg, left ventricular ejection fraction under 30%, critical AS, or any standard contraindication to nitrates.

The clinical logic is straightforward: better coronary visualization means CAD can more often be confidently excluded on CT alone, sparing a same-admission invasive angiogram in a patient already headed for one procedure.

Case in Point

An 81-year-old with symptomatic severe aortic stenosis and a heavily calcified aortic valve is referred for TAVI workup.

Baseline blood pressure is 152/78 mmHg, ejection fraction is 55%, and there is no history of nitrate intolerance.

Following the updated protocol, the CT team gives 0.8 mg of sublingual nitroglycerin five minutes before acquisition.

The resulting scan shows well-opacified, low-noise coronary segments with no significant stenosis, and the heart team proceeds directly to TAVI without a preceding invasive angiogram.

Dosing and Cost

Sublingual nitroglycerin doses in this population have ranged from 0.3 mg to 0.8 mg depending on aortic valve area and institutional protocol.

The drug itself is generic, inexpensive, and widely stocked, which makes this an unusually low-cost intervention with an outsized effect on downstream resource use.

Product	Formulation	Manufacturer	Cash Price (GoodRx)
Nitroglycerin (generic)	0.4 mg sublingual tablet, 25 ct	Multiple generic manufacturers	as low as $9.00
Nitrostat (brand)	0.4 mg sublingual tablet, 25 ct	no ticker (brand marketed by a private generics distributor)	as low as $9.00

Financial disclaimer: stock ratings, price targets, and drug pricing cited in this article are point-in-time snapshots for educational purposes, are not investment advice, and should be independently verified before any clinical or financial decision.

The Investor Lens: Who Benefits from a Streamlined Pre-TAVI Workup

A protocol change that lets more centers safely exclude CAD on CT alone, rather than defaulting to invasive angiography, has ripple effects across the structural heart and cardiac imaging supply chain.

Fewer invasive angiograms per TAVI candidate shifts volume and margin toward CT hardware and toward the valve platforms that depend on efficient, high-throughput screening pipelines.

Company	Ticker	Relevance	Analyst Consensus	12-Mo Price Target
Edwards Lifesciences	NYSE: EW	Leading transcatheter aortic valve (SAPIEN) platform; volume tied to efficient pre-TAVI workup	Buy	$97.58
Medtronic	NYSE: MDT	Competing TAVI platform (Evolut); same CT-dependent screening pathway	Buy	$98.00
GE HealthCare	NASDAQ: GEHC	Major cardiac CT scanner manufacturer; benefits from expanded pre-TAVI CTA volume	Buy	$78.95

Bottom Line

Sublingual nitroglycerin before pre-TAVI coronary CTA, long avoided in severe AS out of caution, appears safe and meaningfully improves image quality in carefully selected, hemodynamically stable patients.

Better images translate directly into fewer equivocal reads, higher diagnostic accuracy, and a real chance to skip an unnecessary invasive angiogram in a patient already facing one procedure.

Cardiologists running structural heart imaging programs should revisit their own institutional protocols and exclusion criteria in light of this evidence.

---

References

1. SCCT 2026: What to Expect in Chula Vista. TCTMD.
2. New CT Guidelines for TAVR Emphasize Standardization, 4-D Acquisition, and Postprocedural Imaging. TCTMD.
3. Nitroglycerin Prices, Coupons and Savings Tips. GoodRx.
4. Edwards Lifesciences (EW) Stock Forecast & Price Targets. StockAnalysis.com.
5. Medtronic (MDT) Stock Forecast & Analyst Price Targets. StockAnalysis.com.
6. GE HealthCare Technologies (GEHC) Stock Forecast & Price Targets. StockAnalysis.com.

Physician education disclaimer: this article summarizes preliminary conference-presented data and is intended for physician education, not as a substitute for institutional protocols, product labeling, or individualized clinical judgment.

Cardiac Imaging & Market Watch

One Heartbeat, Almost No Radiation: FLASH Photon-Counting CCTA Comes of Age for Young, Low-Risk Patients

Clinical synthesis with an investor lens for physician-investors in cardiovascular imaging

A new prospective registry presented at the 2026 Society of Cardiovascular Computed Tomography meeting suggests that young, low-risk patients referred for coronary CT angiography can be scanned with almost no radiation at all.

Using a single-heartbeat, high-pitch acquisition technique called FLASH on a fourth-generation photon-counting CT scanner, investigators achieved a median effective dose of just 0.82 mSv.

That is lower than the radiation from a routine coronary calcium score, long considered the lowest-dose cardiac CT test available.

For physicians who order or perform cardiac CT, this data point reframes what a "low-radiation" coronary study can look like in practice.

Figure 1. Approximate effective radiation doses across common cardiac imaging protocols, shown for orientation rather than head-to-head comparison.

What the Registry Showed

Investigators enrolled 70 patients with no known coronary disease referred for CCTA, with a mean age of 36 and 41% women.

All scans used the FLASH protocol, a prospective high-pitch helical acquisition that captures the entire heart in a single cardiac cycle rather than over several heartbeats.

Scanning was performed on a fourth-generation dual-source photon-counting CT scanner (marketed as NAEOTOM Alpha).

Mean body mass index was 26.5 kg/m² and mean heart rate was 58 beats per minute, reflecting careful patient selection.

More than half the cohort (59%) had dyslipidemia, and just over half (51%) had a family history of premature coronary disease.

Effective radiation dose fell below 1 mSv in 70% of patients, with a median of 0.82 mSv for the full cohort.

Image quality was rated excellent in 51% and good in 27%, while 9% of scans (six patients) were nondiagnostic and required a repeat study.

On CAD-RADS scoring, 81% of patients were classified as CAD-RADS 0 and 16% as CAD-RADS 1, meaning 97% had no or minimal disease.

One patient was scored CAD-RADS 2, and one was scored CAD-RADS 4A, a finding that was subsequently confirmed by invasive coronary angiography.

Figure 2. CAD-RADS classification among 70 patients scanned with the FLASH photon-counting protocol.

Table 1. FLASH Photon-Counting CCTA Registry at a Glance

Parameter	Result
Cohort size	70 patients
Mean age / % women	36 years / 41%
Mean BMI	26.5 kg/m²
Mean heart rate	58 bpm
Median effective dose	0.82 mSv
Dose <1 mSv	70% of patients
Nondiagnostic scans	9% (6 patients)
CAD-RADS 0 or 1	97% of patients

Why a Single Heartbeat Matters

FLASH acquisition is available on most modern CT scanners, but many imagers have been reluctant to use it because it provides only one cardiac phase rather than the multiphase buffer of conventional protocols.

That single-phase design behaves like a bet on the patient's physiology: a steady, slow heart rate produces a crisp image, while an irregular or fast rhythm risks a nondiagnostic study.

The registry's authors framed this trade-off directly, noting that even a failed FLASH scan carries only a small radiation penalty before falling back to a conventional protocol.

Photon-counting detectors add a second, complementary advance by directly registering individual X-ray photons rather than integrating their combined energy.

This design reduces electronic background noise, sharpens spatial resolution, and lessens blooming artifact around calcified plaque and stents, all of which support confident low-dose imaging.

The combination of ultrafast single-beat acquisition with photon-counting detection is what allowed this cohort's median dose to undercut a standard calcium score.

Heart rate control was central to success, and the study team relied on beta-blockers to bring resting heart rates down before scanning.

Patients with a resting heart rate above 70 beats per minute were switched to a conventional prospective protocol rather than attempting FLASH.

Table 2. Common Beta-Blockers Used for Pre-CCTA Heart Rate Control

Generic name	Common brand	Route	Approx. cash price (GoodRx)
Metoprolol tartrate	Lopressor	Oral / IV	~$7–17 per 30-day oral supply
Metoprolol succinate	Toprol XL	Oral, once daily	~$12–20 per 30-day supply

Clinical Vignette

A 34-year-old nonsmoking marketing executive with a strong family history of premature coronary disease and borderline dyslipidemia presents with atypical chest tightness during a stressful workweek.

Her resting heart rate is 56 beats per minute and her calculated pretest probability of obstructive disease is low.

Rather than defaulting to a standard-dose CCTA protocol, her imaging team selects a single-heartbeat FLASH acquisition on their photon-counting scanner after a low dose of oral metoprolol.

The study is read as CAD-RADS 0, delivered at a dose lower than her prior coronary calcium score, and she is reassured and discharged with standard preventive counseling.

Practical Considerations Before Adopting FLASH

Both patient body size and heart rate variability determine candidacy, and sinus arrhythmias common in younger patients can still be accommodated with careful protocolling.

A resting heart rate that is too high or too variable is the most common reason to abandon FLASH in favor of a conventional prospective, multiphase acquisition.

Radiology and cardiology teams, along with their technologists, need shared buy-in before rolling out a low-dose FLASH pathway, since patient selection drives success.

The authors specifically plan to prioritize this protocol for younger patients with chest pain who need coronary anatomy clarified, including evaluation for anomalous coronary arteries.

Broader adoption also intersects with a decade-long trend of falling CCTA radiation doses as scanner technology and protocols have matured industry-wide.

The Business of Photon-Counting CT

The scanner used in this registry is manufactured by Siemens Healthineers AG, whose Imaging division is the commercial home for its photon-counting CT platform.

Siemens Healthineers trades in the US as an OTC ADR and on its primary Frankfurt listing, giving investors two ways to track the same underlying business.

Photon-counting CT has been repeatedly highlighted by company leadership as a growth driver within the broader Imaging segment.

Table 3. Siemens Healthineers AG — Company Snapshot

Metric	Value
Ticker (US OTC)	SMMNY
Primary listing	Frankfurt Stock Exchange (SHL)
Recent share price (OTC)	~$20.26 (as of Jun 9, 2026)
Relevant segment	Imaging (CT, MRI, X-ray, ultrasound)
Analyst consensus / 12-mo target	Not published on StockAnalysis.com for the OTC listing at time of writing

Because stock prices and analyst estimates move continuously, treat the figures above as a point-in-time snapshot rather than a current quote.

Bottom Line

In carefully selected young, low-risk patients with controlled heart rates, single-heartbeat FLASH acquisition on a photon-counting CT scanner can deliver diagnostic-quality coronary imaging at a radiation dose below that of a standard calcium score.

Success depends heavily on patient selection, heart rate control, and institutional readiness rather than the technology alone.

For physician-investors, the data reinforce photon-counting CT as a durable growth narrative for imaging equipment manufacturers, independent of any single stock's near-term price action.

Want this turned into a short video script, a social media summary, or a patient-facing handout on low-radiation heart CT? Just ask.

References

1. TCTMD conference coverage of SCCT 2026, Chula Vista, CA, July 9–12, 2026.
2. Society of Cardiovascular Computed Tomography news release on CAD-RADS 2.0.
3. FDA patient guidance on radiation risks from CT.
4. StockAnalysis.com company profile for Siemens Healthineers AG.
5. GoodRx pricing information for metoprolol.

Physician education disclaimer: This article is intended for physician education and reflects a synthesis of publicly available conference and industry data as of the date of writing; it is not a substitute for full peer-reviewed publication, institutional protocols, or individualized clinical judgment.

Financial disclaimer: Stock tickers, prices, and company information are provided for general educational context only, reflect a single point in time, and do not constitute investment advice or a recommendation to buy or sell any security.

The Power of Zero, Revisited: Should a Zero Coronary Calcium Score Still Reassure Symptomatic Patients?

New PROMISE trial data presented at SCCT 2026 show that noncalcified plaque on CCTA reclassifies risk in a meaningful minority of CAC-zero patients with chest pain, reigniting a debate over how far quantitative plaque assessment should extend into everyday practice.

Cardiology & Investing Insights · Preventive Cardiology / Cardiac Imaging

For a generation of cardiologists, a coronary artery calcium (CAC) score of zero has functioned as a reassuring off-ramp for symptomatic patients undergoing chest pain evaluation.

New data presented at the 2026 Society of Cardiovascular Computed Tomography (SCCT) meeting complicate that reassurance for a meaningful subset of patients.

Investigators analyzing the PROMISE trial found that 12% of symptomatic, CAC-zero patients had noncalcified plaque on coronary computed tomography angiography (CCTA), and that this group carried a nearly sixfold higher risk of major adverse cardiac events (MACE).

The findings arrive as AHA guidance on nonobstructive coronary artery disease has already pushed clinicians toward more individualized, plaque-informed decision-making rather than calcium-score shortcuts.

What the PROMISE Reanalysis Showed

The analysis included 3,722 PROMISE participants who underwent CCTA with quantitative plaque assessment (QPA), of whom 40% had a CAC score of zero.

Among CAC-zero patients, those with noncalcified plaque were slightly older, less often female, and had a stenosis rate of 50% or greater that was roughly double that of CAC-zero patients without plaque.

Overall MACE was far higher with CAC present than absent (3.9% vs 1.2%), but once noncalcified plaque was factored in, event rates converged regardless of whether calcium was present (4.5% vs 3.9%).

Critically, the MACE rate fell to just 0.8% in patients with neither CAC nor noncalcified plaque, the group the presenting investigator termed the true "power of zero plaque."

On adjusted analysis, CAC-zero patients with noncalcified plaque had almost six times the hazard of MACE compared with CAC-zero patients without plaque, a signal that was attenuated but not eliminated after accounting for stenosis severity, ASCVD risk, and baseline statin or aspirin use.

MACE Rates Across CAC and Plaque Strata

Median follow-up 25 months, PROMISE trial reanalysis

Two Views From the Podium

The presenting investigator argued for extending plaque assessment specifically to the CAC-zero subgroup, reasoning that most of these patients can be confidently downgraded while a minority are unmasked as truly high-risk.

A discussant offered a more skeptical counterpoint, noting that "zero CAC does not guarantee zero risk" is already well established, and that the more relevant questions are how often the signal appears, how strong it is, and what it costs to chase.

That discussant highlighted that more than half of all MACE events in the CAC-zero group occurred in patients without any noncalcified plaque, undercutting the idea that a negative QPA result offers airtight reassurance.

Using data from a separate national imaging cohort, he estimated that finding one additional true-positive patient via CCTA rather than CAC scoring costs roughly $24,500 more, and that adding QPA on top pushes the cost of detecting one event-bound, noncalcified-plaque-positive patient to about $280,000.

Incremental Cost to Detect One Event-Bound Patient

Illustrative figures cited in SCCT 2026 cost-effectiveness debate

PROMISE-Derived Risk Snapshot

Table 1. MACE and stenosis rates by CAC and plaque status (PROMISE reanalysis, median follow-up 25 months)

Group	Proportion of CAC-zero cohort	≥50% stenosis	MACE rate
CAC zero, no noncalcified plaque	88%	9%	0.8%
CAC zero, noncalcified plaque present	12%	22%	4.5%
CAC present (any plaque)	—	—	3.9%
All CAC-zero patients (composite)	100%	1.1%	1.2%

Where This Leaves Practice Today

No professional society currently recommends routine QPA for patients who already have a CAC score of zero, so today's decision remains a judgment call rather than a guideline mandate.

For a symptomatic patient whose pretest risk is otherwise low, a zero CAC score plus normal symptoms and risk factors still supports conservative management and rescanning in 5 to 7 years, per existing chest pain guidance.

For patients with amplified risk-factor burden, atypical or escalating symptoms, or a strong family history despite a zero CAC score, added CCTA with plaque quantification is a reasonable discussion point rather than a reflexive order.

Two AI-enabled quantitative plaque analysis platforms, Cleerly and HeartFlow, have driven much of the recent expansion in reimbursed, automated plaque quantification and are the software layer underlying most QPA discussed in this debate.

Both platforms run on CT hardware from major imaging manufacturers, including GE HealthCare, whose installed base of cardiac CT scanners is a key channel for QPA adoption.

Relevant Public Companies

Table 2. Selected companies in the CCTA / quantitative plaque assessment ecosystem

Company	Role	Ticker	Analyst consensus	12-month price target
HeartFlow, Inc.	AI-based FFR-CT and plaque analysis software	NASDAQ: HTFL	Strong Buy	~$37
Cleerly	AI-driven quantitative coronary CT plaque platform	no ticker (private)	N/A	N/A
GE HealthCare Technologies	Cardiac CT imaging hardware	NASDAQ: GEHC	Buy	~$79

Cleerly remains privately held with no public ticker; figures for publicly traded companies reflect analyst consensus at the time of writing and will move with the market.

Clinical Vignette

A 54-year-old active patient with hypertension and a family history of premature coronary disease presents with several months of exertional chest tightness.

A CAC scan returns a score of zero, and the referring clinician is prepared to reassure the patient and stop the workup.

Given the atypical but progressive symptom pattern and multiple risk factors, the cardiologist instead proceeds to CCTA, which reveals a moderate segment of noncalcified plaque without flow-limiting stenosis.

Rather than reflexively escalating to invasive angiography, the patient is started on high-intensity statin therapy and scheduled for close clinical follow-up, illustrating how plaque data—not the calcium score alone—can recalibrate a preventive care plan.

Bottom Line

A CAC score of zero still identifies a large majority of symptomatic patients as truly low risk, but roughly one in eight will harbor noncalcified plaque that meaningfully raises MACE risk.

Quantitative plaque assessment adds real discriminatory value in this subgroup, yet its added cost, currently estimated near $1,000 beyond the CCTA itself, means it is not yet ready for indiscriminate use in all CAC-zero patients.

The most defensible approach today reserves added CCTA and plaque quantification for CAC-zero patients whose symptom pattern or risk-factor burden raises independent concern, rather than applying it universally.

Downstream Practice Note

Clinicians should expect QPA costs to fall as competing AI vendors expand and as reimbursement pathways mature, which may shift this cost-benefit calculation within a few years.

Larger, prospective outcome trials with longer follow-up are still needed before quantitative plaque assessment can be formally incorporated into chest pain guidelines for CAC-zero patients.

Physician education disclaimer: This article is intended for healthcare professional education and summarizes recently presented and published data; it does not constitute clinical practice guidance for any individual patient and should not replace independent clinical judgment or current society guidelines.

Financial disclaimer: Stock tickers, analyst ratings, and price targets referenced above are for informational purposes only, reflect data available at the time of writing, and are not investment advice; consult a licensed financial advisor before making investment decisions.

References

1. TCTMD. Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults.
2. American Heart Association. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain. Circulation.
3. JACC: Cardiovascular Imaging. The Fallacy of the Power of Zero.
4. Cleerly. Personalized Analysis and Treatment of Heart Disease.
5. HeartFlow, Inc. Announces Pricing of Upsized Initial Public Offering.
6. StockAnalysis.com. GE HealthCare Technologies (GEHC) Stock Overview.

Want this adapted into a short video script, a social media summary, or a plain-language patient handout on what a "zero calcium score" does and doesn't mean? Just say the word.

Stroke & Interventional Cardiology · Practice-Changing Data

Tenecteplase vs Alteplase: Why Minutes Saved at the Bedside Are Reshaping Stroke Thrombolysis

6-minute read · Physician & physician-investor briefing

Case Snapshot

A 68-year-old presents to a small community emergency department with acute-onset left-sided weakness and slurred speech, last known well 90 minutes prior.

Non-contrast CT head is negative for hemorrhage, and the patient meets criteria for IV thrombolysis, but the nearest thrombectomy-capable center is 45 minutes away by ground transport.

The treating physician must choose a thrombolytic knowing that whichever agent is chosen will directly determine how quickly the ambulance crew can depart for the receiving hospital.

This is precisely the workflow bottleneck that recent registry data on thrombolytic choice have been designed to address.

Across US stroke systems, the default thrombolytic for acute ischemic stroke is quietly shifting from alteplase to tenecteplase.

A large American Heart Association registry analysis now quantifies exactly how much time that switch saves.

The findings matter less because tenecteplase is dramatically more effective and more because it removes friction from a process where every minute of delay costs neurons.

The Pharmacologic Case for Switching

Tenecteplase is a genetically engineered variant of alteplase with a longer half-life and greater fibrin specificity.

That longer half-life allows tenecteplase to be given as a single five-to-ten-second intravenous bolus, whereas alteplase requires a small bolus followed by a full hour of continuous infusion.

For a hospital without a critical care ambulance capable of managing a running infusion, that hour-long infusion has historically forced a delay before transfer to a thrombectomy center could even begin.

Removing that delay is the core operational advantage driving adoption, independent of any difference in clinical outcomes.

Feature	Tenecteplase (TNKase)	Alteplase (Activase)
Administration	Single IV bolus, 5–10 seconds	Bolus + 60-minute infusion
Half-life	~20–24 minutes	~4–5 minutes
Fibrin specificity	Higher	Lower
FDA indication for AIS	Approved (2024)	Approved (original standard)
Manufacturer	Genentech (Roche Holding, OTC: RHHBY)	Genentech (Roche Holding, OTC: RHHBY)
Cash price (US, per treatment kit)	~$6,500 (50 mg kit)	~$8,600 (100 mg vial)

What the Registry Data Show

New evidence

An analysis of the Get With The Guidelines-Stroke registry covering more than 133,000 patients across roughly 2,000 US hospitals found that door-to-needle time was meaningfully shorter with tenecteplase than with alteplase.

Mean door-to-needle time was about 47 minutes with tenecteplase versus about 53 minutes with alteplase, a difference of roughly three minutes after adjustment.

Tenecteplase-treated patients were also more likely to be treated within the guideline-recommended 30-, 45-, and 60-minute thresholds at every cutoff studied.

Among patients transferred for higher-level care, door-in-door-out time was shorter with tenecteplase both overall and specifically when the transfer was for mechanical thrombectomy.

Confirms prior signal

These findings echo smaller single-center and regional studies, including a comprehensive stroke center registry and a New Zealand stroke network transition, both of which independently reported faster door-to-needle times after switching to tenecteplase.

Adjusted mean workflow times from the GWTG-Stroke registry analysis of over 133,000 patients treated at nearly 2,000 US hospitals.

Efficacy and Safety: Noninferior, Not Superior

The randomized AcT trial, which underpinned FDA approval, showed comparable rates of favorable functional outcome between tenecteplase and alteplase in patients treated within 4.5 hours of symptom onset.

Rates of intracerebral hemorrhage at 24 hours were also similar between the two agents in that trial.

A separate Chinese randomized trial and a large US comparative-effectiveness study built on the same GWTG-Stroke infrastructure independently reported similar short-term safety and effectiveness between the two drugs.

Where tenecteplase has not shown benefit is in extending the treatment window: the TIMELESS trial found no improvement in 90-day outcomes when tenecteplase was given 4.5 to 24 hours after onset in imaging-selected patients.

By contrast, the BRIDGE-TNK trial found that giving IV tenecteplase before mechanical thrombectomy in large-vessel-occlusion stroke improved 90-day functional independence compared with thrombectomy alone.

Trial / Analysis	Population	Key Finding	Classification
AcT (FDA approval basis)	~1,600 patients, ≤4.5h	Noninferior functional outcome, similar ICH rate	Confirmatory
GWTG-Stroke workflow analysis	133,228 patients, 2,092 hospitals	Shorter DTN and DIDO with tenecteplase	New evidence
TIMELESS	Imaging-selected, 4.5–24h	No benefit in extended window	New evidence
BRIDGE-TNK	LVO stroke pre-thrombectomy	Improved 90-day functional independence	New evidence

Adoption Curve and the Investor Lens

Tenecteplase use across GWTG-Stroke hospitals rose from about 1% of thrombolysis cases in mid-2020 to nearly 27% by mid-2022, and clinicians surveyed more recently describe the switch as now nearly universal at larger centers.

Both agents are marketed in the US by Genentech, a wholly owned subsidiary of Roche Holding AG, so the shift is largely a within-company mix change rather than a competitive share loss.

For a physician-investor, the more interesting angle is downstream: faster, more standardized thrombolysis workflows increase the pool of patients arriving in time for thrombectomy, which supports device volumes for the major neurothrombectomy players.

Tenecteplase's share of GWTG-Stroke thrombolysis cases increased roughly 24-fold over two years; national adoption is understood to be substantially higher today.

Practical Takeaways for the Stroke Team

Centers still using alteplase as first-line therapy should reassess given the consistent, if modest, workflow advantage of tenecteplase across multiple independent datasets.

The advantage is likely to matter most at spoke hospitals that lack critical-care transport and depend on rapid transfer to a hub for thrombectomy.

Simpler reconstitution and single-bolus dosing may also reduce the risk of preparation or administration error relative to a weight-based bolus-plus-infusion regimen.

Because tenecteplase costs less per treatment than alteplase in most US contracts, the switch can be workflow-positive and budget-neutral or budget-favorable at the same time.

Bottom Line

Tenecteplase and alteplase appear clinically noninferior for standard-window acute ischemic stroke, but tenecteplase's single-bolus dosing consistently shortens door-to-needle and door-in-door-out times by several minutes.

Given that stroke outcomes are strongly time-dependent, that workflow advantage — not superior efficacy — is the primary driver behind the ongoing national shift away from alteplase.

Physician education disclaimer: This article is intended for healthcare professional education and summarizes publicly available registry and trial data; it is not a substitute for institutional protocols, prescribing information, or individualized clinical judgment.

Financial disclaimer: Stock tickers, analyst data, and pricing figures are provided for informational context only, reflect a point in time, and do not constitute investment advice; consult a licensed financial advisor before making investment decisions.

References

1. TCTMD: AHA/ASA Release New Comprehensive Acute Ischemic Stroke Guideline
2. TCTMD: FDA Approves Tenecteplase for Acute Ischemic Stroke
3. TCTMD: TIMELESS Trial Coverage
4. TCTMD: BRIDGE-TNK Trial Coverage
5. Medscape Reference: Alteplase Dosing and Prescribing Information
6. StockAnalysis.com: Roche Holding AG (RHHBY)

Happy to turn this into a short YouTube script, a one-paragraph social summary, or a patient-facing explainer on stroke thrombolysis if useful — just let me know.

Australia's Retirement Model Comes to Washington: What It Means for Physician-Investors

A White House study directive, a $3.1 trillion pension system, and the health care names riding the growth-stock wave

President Trump has directed Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick to formally study Australia's superannuation system as a template for reforming U.S. retirement savings.

The comments came on July 6 alongside BlackRock's leadership, whose CEO has spent years publicly urging the U.S. to adopt Australia's approach.

For physicians managing 401(k)s, 403(b)/cash balance plans, and backdoor Roth conversions, this is a policy signal worth tracking, not a reason to change anything today.

It also intersects with a second theme worth a physician-investor's attention this month: which publicly traded health care names are showing up on 2026 growth-stock screens.

What Actually Happened

Trump said Australia's system has "really worked out very well" and that his administration intends to study it, and possibly improve on it, in talks with Congress.

No legislation exists yet, and any real proposal is likely years away.

Senator Ted Cruz publicly backed the idea and says he is drafting legislation aimed at extending retirement wealth-building to gig workers and hourly employees.

How Australian Superannuation Works

Australia's superannuation system began in the early 1990s, mandating that employers contribute a fixed percentage of every worker's wages, including part-time workers, into privately managed retirement accounts.

That contribution rate has climbed to roughly 12% of salary, producing a national retirement pool worth about $3.1 trillion, on pace to become the world's second-largest retirement system within a decade.

Feature	Australia (Superannuation)	United States (401(k)/Social Security)
Employer contribution	Mandatory, ~12% of wages	Optional, employer-dependent
Coverage	Universal, including part-time/gig	~60% of private-sector workers
Management	Privately managed, worker-owned account	Mix of private DC plans + government-run Social Security
System size	~$3.1 trillion	Social Security trust fund projected depleted by 2032

Why the Comparison Is Landing Now

The Social Security trust fund is projected to be depleted by 2032, which would trigger automatic benefit cuts absent Congressional action.

Private savings look thin in parallel: among roughly 5 million savers in Vanguard-administered 401(k)-type plans, the median account balance was just $44,115, and that figure excludes the estimated 40% of private-sector workers with no employer plan access at all.

The Skeptics' Case

Retirement policy experts are notably more cautious than the political rhetoric.

The U.S. still owes benefits already promised to current retirees, funded mainly through payroll taxes, so a new mandatory system doesn't erase that transition liability.

Mandatory employer contributions at this scale would likely draw strong business pushback, echoing an Australian argument that such mandates simply divert money from wage growth, though economists remain divided on that point.

A senior adviser at Boston College's Center for Retirement Research has argued that Australians face the same decumulation problem Americans do, turning a lump sum into an income stream that lasts through retirement, and that the U.S. combination of privately managed 401(k)s with inflation-adjusted Social Security is already reasonably well designed.

Some officials have floated a sovereign wealth fund to backstop any Social Security shortfall, an idea a Brookings Institution retirement-security director has flagged as carrying its own real economic tradeoffs.

Physician-Investor Takeaways

Nothing here changes your 2026 contribution limits or account strategy today, since this is a study directive, not legislation.

BlackRock (NYSE: BLK)BLK is positioned as an intellectual architect of this conversation, and asset managers with retirement-plan infrastructure and target-date fund platforms would stand to benefit from any expanded contribution flows.

If a mandatory contribution model ever reached physician employers such as hospital systems or private-practice groups, it would likely layer on top of existing 403(b)/401(k) and cash balance plan structures rather than replace them.

The more immediate, bipartisan-adjacent thread to watch is the Trump Accounts program for children, which currently has more political momentum than any adult system overhaul.

Visual: Contribution Structure at a Glance

Illustrative comparison of typical U.S. employer 401(k) match versus Australia's mandatory 12% superannuation contribution.

Growth-Stock Screens: Where Health Care Names Show Up

Separately, this month's 10-year growth-stock screens continue to feature a familiar cardiometabolic name alongside AI-infrastructure and semiconductor plays.

Eli Lilly (NYSE: LLY)LLY is highlighted for its leadership in obesity, diabetes, and oncology, with Mounjaro and Zepbound cited as the growth drivers reshaping long-term revenue expectations.

Novo Nordisk (NYSE: NVO)NVO, while not on every screen, remains the other half of the incretin duopoly physicians will recognize from clinic, with Ozempic and Wegovy as its flagship semaglutide brands.

Company	Ticker	Analyst Consensus	Notable Products (Physician-Relevant)
BlackRock	BLK	Strong Buy	Retirement-plan infrastructure, target-date funds
Eli Lilly	LLY	Buy / Strong Buy	Mounjaro, Zepbound, Verzenio, Jardiance
Novo Nordisk	NVO	Buy (mixed)	Ozempic, Wegovy

Visual: Analyst Price Target vs. Current Price

Approximate implied upside based on recent average analyst price targets versus recent trading prices; ranges vary widely by source and update frequently.

What GLP-1 Pricing Looks Like Right Now

Physicians fielding cost questions from patients on incretin therapy will recognize the gap between list price and negotiated cash pricing.

Brand (Generic)	Manufacturer	Approx. Retail List Price	Approx. Cash/Coupon Price
Ozempic (semaglutide)	Novo Nordisk (NVO)	~$1,223/mo	as low as $149–$349/mo
Wegovy (semaglutide)	Novo Nordisk (NVO)	~$1,646/mo	as low as $149–$349/mo
Mounjaro (tirzepatide)	Eli Lilly (LLY)	~$1,348/mo	as low as $25–$1,087/mo with savings card

Clinical & Financial Case Vignette

A 52-year-old interventional cardiologist employed by a large health system asks whether she should adjust her retirement contributions given the news about an Australian-style savings mandate.

Her practice already offers a 403(b) with employer match and a cash balance plan tied to her wRVU production.

The correct answer today is to change nothing, since no legislation exists and any mandate, if it ever passes, would most plausibly sit on top of her existing plans rather than replace them.

Separately, a patient on Wegovy for obesity and cardiovascular risk reduction asks why her pharmacy quoted $1,646 for a drug her friend pays $349 for, prompting a practical conversation about manufacturer savings cards versus cash-pay coupons.

Bottom Line

Australia's superannuation model is now part of the Washington policy conversation, but it remains a study directive, not law, and physicians should not alter contribution strategy based on it today.

BlackRock stands to benefit structurally if any legislative vehicle for expanded retirement infrastructure emerges, while Eli Lilly and Novo Nordisk continue to anchor both growth-stock screens and physician-facing cardiometabolic prescribing.

References

1. Trump embraces Australian retirement system backed by Larry Fink, Bloomberg via Fortune, July 12, 2026.
2. 9 Best Growth Stocks for the Next 10 Years, U.S. News & World Report via WTOP, updated May 2026.
3. BlackRock (BLK) Stock Forecast & Analyst Price Targets, StockAnalysis.com.
4. Eli Lilly (LLY) Stock Forecast & Price Targets, StockAnalysis.com.
5. Novo Nordisk (NVO) Stock Forecast & Analyst Price Targets, StockAnalysis.com.
6. Ozempic Prices, Coupons & Savings Tips, GoodRx.
7. Wegovy Prices, Coupons & Savings Tips, GoodRx.
8. Mounjaro Coupons, Cost & Savings Cards, GoodRx.

Physician education disclaimer: This article is intended for physician education and general awareness of policy and market developments; it does not constitute personalized financial, legal, or clinical advice for any individual patient or reader.

Financial disclaimer: Nothing in this article is investment advice. Stock prices, analyst price targets, and drug pricing change frequently and should be independently verified before any financial or clinical decision. The author is not a licensed financial advisor.

Closing the CKM Treatment Gap: What the Latest NHANES Data Mean for Practice and Pharma

Cardiometabolic Care · Practice & Policy

New national survey data show that even high-risk patients with cardiovascular-kidney-metabolic syndrome are falling short of blood pressure, lipid, and glucose targets — and the shortfall is worst where it matters most.

A Familiar Diagnosis Gets a New Name

Cardiovascular-kidney-metabolic (CKM) syndrome describes the overlapping biology of obesity, dysglycemia, hypertension, chronic kidney disease, and atherosclerotic disease.

The American Heart Association first framed the syndrome in a 2023 presidential advisory.

A full joint AHA/ACC/ADA/ASN guideline followed this June, formalizing a five-stage classification from stage 0 (no risk factors) through stage 4 (clinical cardiovascular disease).

New data drawn from the National Health and Nutrition Examination Survey (NHANES) now put a number on how well the country is actually managing this population.

The short answer is: not well, and least well in the patients who stand to lose the most.

What the Numbers Show

Investigators analyzed 6,384 adults with stage 2 or higher CKM syndrome enrolled in NHANES between 2015 and 2023.

Most had hypertension or hyperlipidemia, and roughly one in five had diabetes.

Treatment rates, adjusted for age and sex, were highest for diabetes and lowest for hyperlipidemia.

Among those actually receiving treatment, fewer than half of patients with hypertension or diabetes reached guideline-concordant control.

Age- and sex-adjusted treatment rates and among-treated control rates, NHANES 2015–2023, stage 2+ CKM syndrome.

Risk Factor	Treatment Rate	Control Rate (Among Treated)	8-Year Trend
Hypertension	51.3%	44.7% (BP <130/80 mm Hg)	Declining
Hyperlipidemia	48.8%	68.2% (total cholesterol <200 mg/dL)	Treatment declining; control improving (64.7%→76.5%)
Diabetes	83.4%	47.3% (A1c <7%)	Treatment rising; control flat

The Paradox: Higher Risk, Worse Control

Patients were also stratified by the AHA PREVENT equations into low-to-borderline, intermediate, and high 10-year cardiovascular risk tiers, plus a group with established disease.

Higher-risk patients were more likely to be started on treatment for hypertension and hyperlipidemia.

Yet blood pressure control became less likely, not more likely, as predicted risk climbed.

Glycemic control was worst among patients who already had established cardiovascular disease.

Cholesterol control was the one metric that improved in step with rising risk.

Demographic gaps compounded the problem: young adults, women, and Hispanic adults had the lowest treatment initiation rates across the board.

Black patients had poorer blood pressure control than white patients despite similar treatment rates.

PREVENT Risk Tier	Treatment Pattern	Control Pattern
Low-to-borderline (<7.5%)	Lower initiation for HTN and lipids	Relatively preserved BP control
Intermediate (7.5–<20%)	Increasing initiation	Progressive decline in BP control
High (≥20%) / established CVD	Highest initiation for HTN and lipids	Worst BP and glycemic control

From "Who Gets Treated" to "Who Gets to Goal"

An accompanying editorial from investigators at a large academic health system framed this as an "intensification gap" rather than a simple access problem.

The editorialists argue that the more actionable signal is not undertreatment of low-risk patients, but insufficient escalation of therapy in the highest-risk group.

Therapeutic inertia is the likely culprit: clinicians start a medication, but asymptomatic risk factors rarely trigger the same follow-through as symptomatic disease.

Closing the gap, the editorial suggests, will require more consistent blood pressure and A1c monitoring, structured uptitration protocols, and system-level support rather than reliance on a single office visit.

CKM syndrome staging framework; the NHANES treatment-gap analysis focused on stage 2 and above, where 90–95% of US adults now fall.

The Expanding Drug Toolbox

Two drug classes anchor modern CKM-directed therapy: GLP-1 receptor agonists and SGLT2 inhibitors.

Both classes now carry cardiovascular and renal outcome benefits that extend well beyond glycemic control.

Uptake, however, remains far below the eligible population, and pricing is a major barrier for cash-paying patients.

Agent (Generic / Brand)	Class	Manufacturer	Analyst Consensus	GoodRx Cash Price
Semaglutide (Ozempic)	GLP-1 RA	Novo NordiskNVO	Buy (PT $47.91)	From $149/mo with coupon
Semaglutide (Wegovy)	GLP-1 RA	Novo NordiskNVO	Buy (PT $47.91)	From $149/mo with coupon
Tirzepatide (Mounjaro)	GIP/GLP-1 RA	Eli LillyLLY	Buy (PT $1,240.46)	From ~$1,087/mo with coupon
Empagliflozin (Jardiance)	SGLT2 inhibitor	Boehringer Ingelheimno ticker (private) / Eli LillyLLY	Buy (PT $1,240.46, LLY)	From $249/mo with coupon
Dapagliflozin (Farxiga)	SGLT2 inhibitor	AstraZenecaAZN	Strong Buy (PT ~$221–224)	From $288/mo with coupon

Prices shown are cash, discount-card rates for the most common dose and reflect a single point in time; actual out-of-pocket cost depends on insurance, pharmacy, and manufacturer savings-card eligibility.

A Policy Lever: CMS's ACCESS Model

Payment reform is arriving alongside the pharmacology.

The Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model is a 10-year, voluntary Medicare payment model that launched its first cohort in mid-2026.

ACCESS pays participating organizations recurring, outcome-aligned payments for managing chronic conditions rather than paying for visit volume.

One of its four initial clinical tracks, "Early CKM," specifically targets hypertension, dyslipidemia, obesity, and prediabetes — the exact risk factors highlighted as undertreated in the NHANES analysis.

For employed physicians on wRVU-based compensation, participation questions will hinge on how outcome-based payments interact with existing productivity metrics and whether they flow through to individual clinicians or only to the parent organization.

Clinical Vignette

A 58-year-old patient with type 2 diabetes, stage 3 chronic kidney disease, and a calculated 10-year PREVENT risk of 24% is seen for a routine follow-up.

Blood pressure in clinic is 142/86 mm Hg on a single antihypertensive agent, and the most recent A1c is 7.9% on metformin alone.

Under a traditional visit-based model, a stable-appearing, asymptomatic patient like this is easy to leave unchanged for another interval.

Applying the intensification-gap framework, this is precisely the highest-risk profile in which therapy should be escalated rather than maintained.

A reasonable next step is uptitration of the antihypertensive regimen toward a target below 130/80 mm Hg and initiation of an SGLT2 inhibitor, which addresses glycemic, renal, and cardiovascular risk simultaneously.

Bottom Line

Roughly half of US adults with CKM syndrome who need treatment for hypertension or hyperlipidemia are not receiving it, and fewer than half of those who are treated reach target.

The gap is worst, not best, in patients at the highest predicted cardiovascular risk — a reversal of what risk-based care should look like.

Closing it will depend less on starting new prescriptions and more on systematic uptitration, monitoring infrastructure, and payment models like ACCESS that reward outcomes over visit volume.

For physician-investors, the sustained underuse of GLP-1 and SGLT2 therapy relative to guideline eligibility remains a multi-year demand runway for Novo Nordisk, Eli Lilly, and AstraZeneca, tempered by pricing pressure and increasing competition among agents.

---

Physician Education Disclaimer: This article is intended for licensed healthcare professionals for educational purposes only and does not constitute individualized medical advice. Treatment decisions should be individualized based on patient-specific clinical judgment and current guidelines.

Financial Disclaimer: This content is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Stock prices, analyst price targets, and drug pricing are point-in-time figures that change frequently; consult a licensed financial advisor before making investment decisions.

References

1. NHANES Data Point to Subpar Treatment of Risk Factors in CKM Syndrome. TCTMD.
2. AHA/ACC Release First Comprehensive Guideline on CKM Syndrome. TCTMD.
3. CV Risk Factor Treatment, Control Rates Low Among Adults With CKM. American College of Cardiology.
4. ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model. Centers for Medicare & Medicaid Services.
5. Jardiance Prices, Coupons & Savings Tips. GoodRx.
6. Farxiga Prices, Coupons & Savings Tips. GoodRx.
7. Novo Nordisk A/S (NVO) Stock Price & Overview. StockAnalysis.com.
8. Eli Lilly and Company (LLY) Stock Price & Overview. StockAnalysis.com.
9. AstraZeneca (AZN) Stock Price & Overview. StockAnalysis.com.